Evidence map›Paper›PMID 36323071›Full record

ArticleOral oncology2022

Prognostic value of CD103

Joshua D Smith, Emily L Bellile, Susan E Ellsperman, Molly E Heft-Neal, Jacqueline E Mann, Andrew C Birkeland, Rebecca C Hoesli, Paul L Swiecicki, Francis P Worden, Caitlin Schonewolf and 14 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oral oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Intratumoral CD103Cancer communications (London, England) · 2023
    Article
  10. Review
  11. Association between radiomics features of DCE-MRI and CD8Pathology oncology research : POR · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 1 institution in 1 country.

Joshua D SmithDepartment of Otolaryngology - Head & Neck Surgery, University of Michigan, Ann Arbor, MI 48109, United States.
Emily L BellileDepartment of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI 48109, United States.
Susan E EllspermanDepartment of Otolaryngology - Head & Neck Surgery, University of Michigan, Ann Arbor, MI 48109, United States.
Molly E Heft-NealDepartment of Otolaryngology - Head & Neck Surgery, University of Michigan, Ann Arbor, MI 48109, United States.
Jacqueline E MannDepartment of Otolaryngology - Head & Neck Surgery, University of Michigan, Ann Arbor, MI 48109, United States; Department of Pathology, University of Michigan, Ann Arbor, MI 48109, United States.
Andrew C BirkelandDepartment of Otolaryngology - Head & Neck Surgery, University of Michigan, Ann Arbor, MI 48109, United States.
Rebecca C HoesliDepartment of Otolaryngology - Head & Neck Surgery, University of Michigan, Ann Arbor, MI 48109, United States.
Paul L SwiecickiDivision of Hematology & Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, United States; Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, United States.
Francis P WordenDivision of Hematology & Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, United States; Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, United States.
Caitlin SchonewolfDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109, United States.
Jennifer L ShahDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109, United States.
Michelle L MierzwaDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109, United States.
Andrew J RoskoDepartment of Otolaryngology - Head & Neck Surgery, University of Michigan, Ann Arbor, MI 48109, United States.
Chaz L StuckenDepartment of Otolaryngology - Head & Neck Surgery, University of Michigan, Ann Arbor, MI 48109, United States.
Steven B ChinnDepartment of Otolaryngology - Head & Neck Surgery, University of Michigan, Ann Arbor, MI 48109, United States; Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, United States.
Andrew G ShumanDepartment of Otolaryngology - Head & Neck Surgery, University of Michigan, Ann Arbor, MI 48109, United States.
Keith A CasperDepartment of Otolaryngology - Head & Neck Surgery, University of Michigan, Ann Arbor, MI 48109, United States.
Kelly M MalloyDepartment of Otolaryngology - Head & Neck Surgery, University of Michigan, Ann Arbor, MI 48109, United States.
Mark E P PrinceDepartment of Otolaryngology - Head & Neck Surgery, University of Michigan, Ann Arbor, MI 48109, United States.
Gregory T WolfDepartment of Otolaryngology - Head & Neck Surgery, University of Michigan, Ann Arbor, MI 48109, United States.
Dafydd G ThomasDepartment of Pathology, University of Michigan, Ann Arbor, MI 48109, United States.
Jonathan B McHughDepartment of Pathology, University of Michigan, Ann Arbor, MI 48109, United States.
J Chad BrennerDepartment of Otolaryngology - Head & Neck Surgery, University of Michigan, Ann Arbor, MI 48109, United States; Department of Pathology, University of Michigan, Ann Arbor, MI 48109, United States; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109, United States.
Matthew E SpectorDepartment of Otolaryngology - Head & Neck Surgery, University of Michigan, Ann Arbor, MI 48109, United States; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109, United States. Electronic address: mspector@med.umich.edu.
University of Michigan–Ann Arbor · US

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Alexey I Nesvizhskii · 1988 to 2026
$178.2M
Advanced Research Training in OtolaryngologyT32DC005356 · NIDCD · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CORFAS, GABRIEL · 2002 to 2021
$3.5M
NCI NIH HHS P30 CA046592NIDCD NIH HHS T32 DC005356
6 · The paper itself

Abstract

objectivesIn an evolving era of immunotherapeutic options for persistent or recurrent laryngeal squamous cell carcinoma (LSCC), there is a need for improved biomarkers of treatment response and survival to inform optimal treatment selection and prognostication. Herein, our primary objective was to explore correlations between tumor infiltrating lymphocytes (TILs) and PD-L1 Combined Positive Score (CPS). Secondarily, we sought to explore their combined association with survival outcomes in patients with persistent or recurrent LSCC treated with salvage surgery. MATERIALS AND

methodsThis was a retrospective cohort study at a single academic medical center. Immunohistochemistry staining for TILs and PD-L1 was performed on a tissue microarray of persistent or recurrent LSCC pathologic specimens. Correlations between TIL subsets and PD-L1 CPS were examined using Pearson's correlation coefficient and survival outcomes were analyzed with the Kaplan-Meier method and log-rank tests.

resultsOnly CD103

conclusionAmong patients with persistent or recurrent LSCC, CD103

Indexed as

Head and Neck NeoplasmsLymphocytes, Tumor-InfiltratingB7-H1 AntigenBiomarkers, TumorHumansPrognosisRetrospective StudiesSquamous Cell Carcinoma of Head and NeckB7-H1 AntigenBiomarkers, TumorCD274 protein, humanCD103Combined positive scoreHead and neckLarynxPD-L1Squamous cell carcinomaSurvivalTumor-infiltrating lymphocytes

Identifiers

PMID36323071
PMCPMC10099383
OpenAlexW4308150226

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.